Cryptopolitan on MSN2h
Internet Computer ICP price prediction 2024-2030: Is ICP a good investment?
Key takeaways Internet Computer (ICP) is a groundbreaking blockchain network developed by the DFINITY Foundation. It aims to ...
Wrestlezone on MSN1d
Violent J: ICP Wears Clown Paint And We’re Wild But It Doesn’t Mean JCW Is A Joke
Violent J wants more for JCW. Since launching in 1999, Juggalo Championship Wrestling has attracted a multitude of fans, with ...
Violent J Weighs In On A Potential WWE Hall Of Fame Induction For ICP
Violent J explores the possibility of a WWE Hall of Fame induction. Earlier this year, Eric Bischoff started an unofficial ...
gulftoday4d
ICP says no extension of amnesty period, inspections to begin from Nov.1
Inspection campaigns would be conducted in collaboration with the relevant authorities on overstayers beginning on Nov.1, ...
GlobalData on MSN1d
InnoCare’s Phase II psoriasis therapy trial meets primary endpoint
InnoCare Pharma has announced that its Phase II clinical study of the Tyrosine Kinase 2 (TYK2) inhibitor ICP-488 for ...
FierceBiotech2d
InnoCare's TYK2 inhibitor shows potential to rival Sotyktu in Chinese phase 2 psoriasis trial
InnoCare Pharma’s tyrosine kinase 2 (TYK2) inhibitor has hit the main goals of a phase 2 trial in China, sustaining the ...
诺诚健华：创新药ICP-488Ⅱ期临床试验取得积极结果
每经AI快讯，诺诚健华(688428)10月9日晚间公告，公司创新药ICP-488在中重度斑块状银屑病患者中进行的Ⅱ期随机、双盲、安慰剂对照研究中取得了积极的临床试验结果。研究结果显示，接受6mg和9mg（每日一次）ICP-488治疗的患者在第12周的PASI75较接受安慰剂的患者均有显著的改善。此外，接受ICP-488治疗的患者中，达到PASI90、 ...
诺诚健华ICP-488 Ⅱ期临床试验达到主要终点
公告显示，该项II期临床试验是一项随机、双盲、安慰剂对照试验，以评估ICP-488治疗中重度斑块状银屑病的有效性及安全性。研究的主要终点是在第12周时，银屑病面积和严重度指数（PASI）得分至少减少75%。研究结果显示，接受6mg和9mg（每日一次）ICP-488治疗的患者在第12周的PASI 75较接受安慰剂的患者均有显著的改善。
Fury Samples High-Grade Lithium from Outcrop at Éléonore South
Fury Gold Mines Limited (TSX:FURY)(NYSE American:FURY) (”Fury” or the “Company”) is pleased to announce results from multiple ...
诺诚健华(09969)：治疗中重度斑块状银屑病的ICP-488 II期达到临床研究主要终点
智通财经APP讯，诺诚健华(09969)发布公告，ICP-488(一种每日一次口服TYK2(酪氨酸激酶2)变构抑制剂)在中重度斑块状银屑病患者中进行的Ⅱ期随机、双盲、安慰剂对照研究中取得积极的试验结果。 ICP-488是一种强效的高选择性TYK2(酪氨酸激酶2)变构抑制剂。ICP-488通过结合TYK2-JH2结构域，阻断IL-23、IL-12和I型干扰素等炎性细胞因子的信号转导，从而抑制自身免疫 ...
格隆汇 on MSN2d
诺诚健华(688428.SH)：创新药ICP-488在中重度斑块状银屑病患者中进行的Ⅱ期相关研究中取得积极的临床试验结果
格隆汇10月9日丨诺诚健华(688428.SH)公布，近日获悉，公司创新药ICP-488在中重度斑块状银屑病患者中进行的Ⅱ期随机、双盲、安慰剂对照研究中取得了积极的临床试验结果。ICP-488是一种强效的高选择性口服TYK2（酪氨酸激酶2）变构抑制剂 ...
格隆汇 on MSN2d
诺诚健华(09969.HK)：治疗中重度斑块状银屑病的ICP-488II期达到临床研究主要终点
格隆汇10月9日丨诺诚健华(09969.HK)公告，董事会欣然宣布，ICP-488(一种每日一次口服TYK2(酪氨酸激酶2)变构抑制剂)在中重度斑块状银屑病患者中进行的Ⅱ期随机、双盲、安慰剂对照研究中取得积极的试验结果。